Models In A State Of Transition

Published Sep 17, 2012
Princeton, NJ, USA – It happens to all of us: one day you’re feeling fine and the next day you wake up with a cold. How did you go from the state of being well, to the state of being sick? Health care decision makers examine this process using what are called, state-transition models, which follow the process of a population going from one state of health to the next. Professor Uwe Siebert, MD, MPH, MSc, ScD, lead author on the paper, “State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-3” says, "State-transition modeling is an intuitive, flexible and transparent approach of computer-based decision-analytic modeling. It includes deterministic Markov cohort simulation as well as individual-based Monte Carlo microsimulation. This Task Force report includes recommendations on the structure, data, analysis, and reporting of state-transition models.” State-transition models are used in a variety of ways including evaluation of preventive, screening, diagnostic and treatment strategies. This paper is one of the seven papers in the series on modeling study best practices and is jointly published in Value in Health, the official journal of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and Medical Decision Making, the official journal of the Society for Medical Decision Making (SMDM).

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health. For more information: www.ispor.org

Related Stories

Rethinking Value Assessment for Orphan Drugs

Dec 18, 2024

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that document challenges in rare disease evidence and economic evaluation and policy as well as ways in which the environment is evolving to address them.

ISPOR Releases Emerging Good Practices Guidance on Quantifying Specialized Knowledge in Healthcare

Nov 6, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that identifies existing structured expert elicitation protocols that can support healthcare decision making and provides important insights on how to choose which protocols may be the most appropriate for different scenarios, such as time-constrained decisions, early-stage technology assessments, and public health policies.

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×